A study found that adding immune checkpoint inhibitors to neoadjuvant chemotherapy improved pathologic complete response and event-free survival in certain patients with early-stage breast cancer. However, there was no benefit observed with adjuvant immune checkpoint inhibitor therapy. The study analyzed nine clinical trials with over 5,000 patients, showing that immune checkpoint inhibitors were particularly beneficial for those with triple-negative breast cancer. Despite the improvements in outcomes, patients receiving neoadjuvant immune checkpoint inhibitors also experienced a higher rate of grade 3 or worse adverse events. Researchers suggest that future trials should focus on identifying patients who are most likely to benefit from this treatment approach.
Source link
Neoadjuvant immune checkpoint inhibitor therapy improves outcomes in early breast cancer
